Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855146 | 0.95 | DRD2 (0.55) | DRD2POLBHTR2ADRD3SLC29A1 | |
| SCHEMBL5572674 | 0.90 | POLB (0.59) | DRD2POLBHTR2ADRD3SLC29A1 | |
| SCHEMBL6855574 | 0.87 | POLB (0.49) | DRD2POLBHTR2ADRD3SLC29A1 | |
| SCHEMBL6854656 | 0.87 | DRD2 (0.56) | DRD2POLBHTR2ADRD3SLC29A1 | |
| SCHEMBL5572651 | 0.86 | POLB (0.64) | DRD2POLBHTR2ADRD3SLC29A1 | |
| Hydrochloric Acid SCHEMBL6850866 | 0.86 | DRD2 (0.55) | DRD2POLBHTR2ADRD3SLC29A1 | |
| Hydrochloric Acid SCHEMBL5570686 | 0.85 | POLB (0.63) | DRD2POLBHTR2ADRD3SLC29A1 | |
| Hydrochloric Acid SCHEMBL7031870 | 0.85 | POLB (0.52) | DRD2POLBHTR2ADRD3SLC29A1 | |
| SCHEMBL5572627 | 0.84 | POLB (0.64) | DRD2POLBHTR2ADRD3SLC29A1 | |
| SCHEMBL5570688 | 0.82 | SLC29A1 (0.66) | DRD2POLBHTR2ASLC29A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787653-B2 | REACTING, IN THE PRESENCE OF A METAL CATALYST, A HALOGENOBENZOIC ACID DERIVATIVE WITH BENZENE DERIVATIVE TO PRODUCE BIPHENYLDICARBOXYLIC ACID AMIDE DERIVATIVE | KOWA CO., LTD. (JP) | 2004-09-07 | — | — | US | claimed |
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | US | claimed |
| US-6787653-B2 | REACTING, IN THE PRESENCE OF A METAL CATALYST, A HALOGENOBENZOIC ACID DERIVATIVE WITH BENZENE DERIVATIVE TO PRODUCE BIPHENYLDICARBOXYLIC ACID AMIDE DERIVATIVE | KOWA CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| WO-2003104213-A1 | PREPARATION PROCESS OF BIPHENYLCARBOXYLIC ACID AMIDE DERIVATIVES | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | CD22, C9, FCGR1A | DRD2 1897/4885HTR2A 3834/4885DRD3 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.